VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B

NCT06092333 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

NIH

Sponsor class

Conditions

Chronic Hepatitis B

Interventions

DRUG: VIR-2218 and peginterferon alfa-2a

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)